Discrepancies in inter-rater agreement on resectability of recurrent glioblastoma: Complementary post-hoc analysis of the prospective, randomized DIRECTOR trial
Neuro-Oncology · 2026
DOI: 10.1093/neuonc/noag103 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Neuro-Oncology, 2026. Verfasst von Philipp Karschnia und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (P.K., N.T., O.S.). Hauptthemen laut MEDLINE: Brain Neoplasms, Glioblastoma, Neoplasm Recurrence, Local, Neurosurgical Procedures. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Marlene and Dr. Dirk Ippen.
Abstract (Originalsprache)
Background
Tumor resection is a prerequisite in many studies of new glioblastoma therapeutics; however, no clear parameters for “resectability” exist. We evaluated inter-rater variability in assessing tumor resectability and potential associations between resectability and survival in a trial cohort of glioblastoma recurrence.
Methods
DIRECTOR (NCT00941460; 9/2009-6/2012) evaluated two dose-dense temozolomide regimens for first recurrent glioblastoma, yielding similar outcomes between arms. Re-resection was allowed before initiation of systemic therapy by institutional decision. Eleven surgical neuro-oncologists (blinded to final outcomes) rated whether a “meaningful resection” was achievable for each recurrent IDH-wildtype glioblastoma based on imaging and clinical data.
Results
MRI scans from 69 patients were available (median age: 58.2 ± 1.1 years, median survival: 10.0 months). Forty patients underwent re-resection (median age: 56.4 ± 1.7 years, median survival: 10.8 months). Surgical decision-making markedly varied between raters, ranging from 30 to 58 of 69 cases being classified as “resectable” (κ = 0.405). In patients who received re-resection, a “meaningful resection” was deemed feasible by >80% of raters in 30/40 cases (75.0%). For patients without re-resection, unanimous agreement on non-resectability occurred in only 3/29 cases (10.4%); and 5/29 tumors (17.2%) were considered resectable by >80% of raters. Knowledge of additional clinical factors virtually never changed MRI-based judgments. While patients who had a complete resection of contrast-enhancing tumor had favorable outcomes, a consensus on resectability by >80% of raters was not associated with prolonged overall survival.
Discussion
Feasibility assessment for re-resection is heterogeneous among neurosurgeons, challenging single-surgeon evaluation of “resectability.” Those findings are limited by the number of surgical raters and the size of the DIRECTOR cohort.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (P.K., N.T., O.S.).
- Department of Neurosurgery, Ludwig-Maximilians-University, Munich, Germany.
- German Cancer Consortium (DKTK), DFKZ Partner Site Munich, Munich, Germany (P.K., N.T., J.-C.T.).
- Department of Medical Oncology and Hematology, University Hospital and University of Zurich, Zurich, Switzerland (E.L.R.).
- Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (H.-G.W., M.W.).
- Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
ORCID-Profile: Philipp Karschnia, Nico Teske, Emilie Le Rhun, Hans-Georg Wirsching, Asgeir S Jakola, Constantin Roder, Daniel P Cahill, Jacob S Young, Wolfgang Wick, Ghazaleh Tabatabai, Joachim P Steinbach, Bogdana Suchorska, Lorenzo Bello, Marike L D Broekman, Michael A Vogelbaum, Yoshua Esquenazi, Oliver Schnell, Michael Weller, Joerg-Christian Tonn
Förderung
- NCI NIH HHS
- Marlene and Dr. Dirk Ippen
Zitieren
APA
Karschnia, P., Teske, N., Le Rhun, E., Wirsching, H. G., Jakola, A. S., Roder, C., Cahill, D. P., Vik-Mo, E. O., Berger, M. S., Young, J. S., Wick, W., Tabatabai, G., Steinbach, J. P., Suchorska, B., Drummond, K. J., Bello, L., Broekman, M. L. D., Vogelbaum, M. A., Esquenazi, Y., …, & Tonn, J. C. (2026). Discrepancies in inter-rater agreement on resectability of recurrent glioblastoma: Complementary post-hoc analysis of the prospective, randomized DIRECTOR trial. Neuro-Oncology. https://doi.org/10.1093/neuonc/noag103
Vancouver
Karschnia P, Teske N, Le Rhun E, Wirsching HG, Jakola AS, Roder C, et al. Discrepancies in inter-rater agreement on resectability of recurrent glioblastoma: Complementary post-hoc analysis of the prospective, randomized DIRECTOR trial. Neuro-Oncology. 2026. doi:10.1093/neuonc/noag103
BibTeX
@article{Karschnia2026,
author = {Karschnia, Philipp and Teske, Nico and Le Rhun, Emilie and Wirsching, Hans-Georg and Jakola, Asgeir S and Roder, Constantin and Cahill, Daniel P and Vik-Mo, Einar O and Berger, Mitchel S and Young, Jacob S and Wick, Wolfgang and Tabatabai, Ghazaleh and Steinbach, Joachim P and Suchorska, Bogdana and Drummond, Katharine J and Bello, Lorenzo and Broekman, Marike L D and Vogelbaum, Michael A and Esquenazi, Yoshua and Schnell, Oliver and Weller, Michael and Tonn, Joerg-Christian},
title = {Discrepancies in inter-rater agreement on resectability of recurrent glioblastoma: Complementary post-hoc analysis of the prospective, randomized DIRECTOR trial},
journal = {Neuro-Oncology},
year = {2026},
doi = {10.1093/neuonc/noag103}
}
EUVIMED